Pfizer (PFE) announced that the European Commission (EC) has approved the use of its XALKORI (crizotinib) for the treatment of patients with non-small cell lung cancer (NSCLC) whose tumors are ROS1 mutation-positive. In late July, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval. XALKORI was previously approved in the EU for the first/second line treatment of NSCLC that expresses the enzyme anaplastic lymphoma kinase (ALK).